𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Search for scaling dimensions for random surfaces with c = 1

✍ Scribed by J. Ambjørn; P. Białas; Z. Burda; J. Jurkiewicz; B. Petersson

Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
455 KB
Volume
342
Category
Article
ISSN
0370-2693

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Large-scale search of single nucleotide
Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C
✍ Naoya Kato; Guijin Ji; Yue Wang; Masanori Baba; Yujin Hoshida; Motoyuki Otsuka; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

Hepatitis C virus (HCV) infection is a major risk factor for developing hepatocellular carcinoma (HCC). The host genetic factors that are involved in the development of HCC in patients with HCV infection remain to be investigated. To search for single nucleotide polymorphisms (SNPs) in HCC susceptib

The forward–backward method with a novel
The forward–backward method with a novel spectral acceleration algorithm (FB/NSA) for the computation of scattering from two-dimensional large-scale impedance random rough surfaces
✍ D. Torrungrueng; Joel T. Johnson 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

## Abstract The forward–backward method with a novel spectral acceleration algorithm (FB/NSA) has been shown to be a very efficient 𝒪(__N__~tot~) iterative method of moments, where __N__~tot~ is the total number of unknowns to be solved, for the computation of electromagnetic wave scattering from t

Combination therapy with thymosin α1 and
Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial
✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr